CAR T cells remain during long-term cancer remission

A number of chimeric antigen receptor (CAR) T cell-based therapies are now approved by the FDA for the treatment of cancer. A study published in Nature found that CAR T cells are still present in two patients who remain cancer-free over a decade after they received CAR T cell therapy as part of a cl...

Descripción completa

Detalles Bibliográficos
Autor principal: Barnes, Katharine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053192/
https://www.ncbi.nlm.nih.gov/pubmed/35603282
http://dx.doi.org/10.1038/s43856-022-00092-w
_version_ 1784696944701997056
author Barnes, Katharine
author_facet Barnes, Katharine
author_sort Barnes, Katharine
collection PubMed
description A number of chimeric antigen receptor (CAR) T cell-based therapies are now approved by the FDA for the treatment of cancer. A study published in Nature found that CAR T cells are still present in two patients who remain cancer-free over a decade after they received CAR T cell therapy as part of a clinical trial.
format Online
Article
Text
id pubmed-9053192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90531922022-05-20 CAR T cells remain during long-term cancer remission Barnes, Katharine Commun Med (Lond) Research Highlight A number of chimeric antigen receptor (CAR) T cell-based therapies are now approved by the FDA for the treatment of cancer. A study published in Nature found that CAR T cells are still present in two patients who remain cancer-free over a decade after they received CAR T cell therapy as part of a clinical trial. Nature Publishing Group UK 2022-03-11 /pmc/articles/PMC9053192/ /pubmed/35603282 http://dx.doi.org/10.1038/s43856-022-00092-w Text en © Springer Nature Limited 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Highlight
Barnes, Katharine
CAR T cells remain during long-term cancer remission
title CAR T cells remain during long-term cancer remission
title_full CAR T cells remain during long-term cancer remission
title_fullStr CAR T cells remain during long-term cancer remission
title_full_unstemmed CAR T cells remain during long-term cancer remission
title_short CAR T cells remain during long-term cancer remission
title_sort car t cells remain during long-term cancer remission
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053192/
https://www.ncbi.nlm.nih.gov/pubmed/35603282
http://dx.doi.org/10.1038/s43856-022-00092-w
work_keys_str_mv AT barneskatharine cartcellsremainduringlongtermcancerremission

Ejemplares similares